ADCs in the Treatment of Breast Cancer and Gastric Cancer and Managing AEs Associated with ADCs

A panel of experts in oncology review the use of antibody drug conjugates (ADCs) in breast and gastric cancers, defining optimal management of ADC-related adverse events.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®

EP. 1: Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

August 18th 2022

After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.

EP. 2: Adverse Event Management With T-DXd in Patients With Breast or Gastric Cancers

August 18th 2022

Contextualizing the use of T-DXd in breast cancer and gastric cancers respectively, panelists highlight optimal management of adverse events in these settings.

EP. 3: Management of Interstitial Lung Disease Related to T-DXd in Breast or Gastric Cancers

August 25th 2022

Focused conversation on the occurrence of interstitial lung disease in patients on antibody drug conjugate therapy for breast or gastric cancers.

EP. 4: Selecting Appropriate Patients with MBC for T-DXd and Counseling for AEs

August 25th 2022

Comprehensive insight to the selection and education of patients for whom ADC therapy is an option in breast or gastric cancers, with regard for pulmonary risk status.

EP. 5: Sequencing Therapy in MBC in Second Line and Beyond

September 1st 2022

Closing out their conversation on the first patient profile, oncology nurse experts consider sequencing therapy following trastuzumab deruxtecan in both breast and GI cancers.

EP. 6: Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy

September 1st 2022

Shifting focus to a patient profile of HER2+ metastatic breast cancer treated with trastuzumab emtansine, oncology nurse experts review risk of peripheral neuropathy and its management.

EP. 7: Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers

September 8th 2022

Shared insight on the clinical utility of trastuzumab emtansine in the second- and third-line settings of breast and gastric cancers.

EP. 8: Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers

September 8th 2022

Expert perspectives on how to best manage adverse events associated with trastuzumab emtansine while treating patients with breast or gastric cancers.

EP. 9: A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer

September 15th 2022

Before closing out their discussion on antibody drug conjugate use in breast cancer management, panelists consider ongoing clinical trials in this setting.

EP. 10: Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia

September 15th 2022

Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.

EP. 11: First- and Second-Line Treatment Options for HER2+ Gastric Cancer

September 22nd 2022

A broad overview of the treatment armamentarium for patients receiving first- or second-line therapy for HER2+ gastric cancer.

EP. 12: T-DXd in HER2+ Gastric Cancer: Managing Neutropenia and Other AEs

September 22nd 2022

Focused discussion on the management of antibody drug conjugate–related adverse events in gastric cancer, with a focus on neutropenia.

EP. 13: Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer

September 29th 2022

Panelists briefly review ongoing clinical trials with trastuzumab deruxtecan in the setting of HER2+ gastric cancers.

EP. 14: Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea

September 29th 2022

Shifting focus to the second patient profile of HER2+ gastric cancer, key opinion leaders highlight the risk and management of diarrhea in this setting.

EP. 15: T-DXd in HER2+ Gastric Cancer: Educating Patients About Risk of Diarrhea

October 6th 2022

Comprehensive insight on the optimal management of diarrhea associated with ADC therapy, with regard to patient education and monitoring during treatment.

EP. 16: Role of the Broader Healthcare Team in Managing AEs Associated With T-DXd

October 6th 2022

Panelists share their perspective on the role of the broader, multidisciplinary healthcare team in managing toxicity associated with trastuzumab deruxtecan therapy.

EP. 17: Novel Clinical Trials With ADCs in Gastric Cancer

October 13th 2022

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.

EP. 18: Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer

October 13th 2022

Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.